NovaBay Pharmaceuticals, Inc. Cash Flow Statement
NBY / Health Care|15 years of annual SEC 10-K data (FY2010-FY2024)
Covers operating cash flow, capital expenditures, free cash flow, share buybacks, and dividends paid across 15 fiscal years. All figures from audited SEC 10-K filings.
NovaBay Pharmaceuticals, Inc. used $5M in operating cash flow and negative free cash flow of $5M in FY2024.
Based on SEC 10-K filings.
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -5.51 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | FY2015 | FY2014 | FY2013 | FY2012 | FY2011 | FY2010 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Income | -$7.2M | -$9.6M | -$10.6M | -$5.8M | -$11.0M | -$9.7M | -$6.5M | -$7.4M | -$13.2M | -$19.0M | -$15.2M | -$16.0M | -$7.0M | -$5.1M | -$4.3M |
| Depreciation & Amortization | $40.0K | $51.0K | $120.0K | $59.0K | $51.0K | $65.0K | $266.0K | $95.0K | $114.0K | $164.0K | $232.0K | $314.0K | $341.0K | $425.0K | $427.0K |
| Operating Cash Flow | -$5.2M | -$4.3M | -$6.7M | -$9.2M | -$4.7M | -$7.9M | -$5.6M | -$6.3M | -$11.7M | -$18.6M | -$15.1M | -$13.0M | -$6.5M | -$3.1M | $2.0M |
| Capital Expenditures | $6.0K | $19.0K | $112.0K | $52.0K | $26.0K | $19.0K | $44.0K | $244.0K | $160.0K | $123.0K | $68.0K | $141.0K | $148.0K | $119.0K | $203.0K |
| Free Cash Flow | -$5.2M | -$4.3M | -$6.8M | -$9.2M | -$4.7M | -$7.9M | -$5.6M | -$6.5M | -$11.8M | -$18.7M | -$15.1M | -$13.1M | -$6.7M | -$3.3M | $1.8M |
| Dividends Paid | - | - | - | - | - | $0 | $0 | - | - | - | - | - | - | - | - |
| FCF Margin | - | - | - | - | - | - | - | -35.7% | -99.4% | -426.4% | -4087.3% | -402.9% | -96.3% | -29.6% | 18.7% |